Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT06144788
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 161 participants
- Registry
-
NCT06144788
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06144788. Randomized; triple masking; primary purpose treatment. Start 2023-11-03 (actual); primary completion 2024-12-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06144788- Content hash
76e3c8b5ba8a32179191fa346a3eb06deb72704df8d79d71807e52ab6f68c442